Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bee venom extract, specifically the Albey product by Stallergenes Greer, is an allergen immunotherapy used for honeybee venom desensitization. In clinical trials, it has been combined with Advax, a non-inflammatory delta inulin-based polysaccharide adjuvant developed by Vaxine, to enhance its immunogenicity. This combination therapy aims to shift the immune response away from IgE-mediated allergy toward a tolerogenic IgG4 response, thereby protecting patients with a history of serious bee sting allergy from rapid-onset systemic allergic reactions. The addition of the Advax adjuvant has been shown to produce earlier, higher, and more sustained specific IgG4 responses compared to venom immunotherapy alone, with good tolerability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bee venom extract.